Takeda reported that zasocitinib, the oral TYK2 inhibitor acquired in a $4 billion deal, met co‑primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis, including superiority versus placebo and an active comparator. The company said more than half of treated patients achieved "clear or almost clear" skin and plans regulatory submissions in 2026. Takeda highlighted tolerability data — the most common adverse events were respiratory infections, colds and acne — and intends to present detailed results at a medical meeting. Zasocitinib is being evaluated across multiple inflammatory indications and in head‑to‑head studies versus competitors, positioning Takeda to compete in the crowded oral immunology space if regulators agree on the safety profile.